mutational status has been shown to be a predictive biomarker of resistance to anti-EGFR monoclonal antibody (mAb) therapy in patients with metastatic colorectal cancer. than in men (42.1%, 374/889, = 0.023). Tumors on the right colon have a higher frequency of mutations than those around the left (57.3% vs. 40.4%, 0.0001). Two in-frame insertion mutations… Continue reading mutational status has been shown to be a predictive biomarker of